Mark Neumann Sells 8,550 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Stock

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Get Rating) EVP Mark Neumann sold 8,550 shares of Intra-Cellular Therapies stock in a transaction on Friday, March 10th. The stock was sold at an average price of $43.34, for a total value of $370,557.00. Following the sale, the executive vice president now owns 57,357 shares of the company’s stock, valued at $2,485,852.38. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Mark Neumann also recently made the following trade(s):

• On Wednesday, March 1st, Mark Neumann sold 7,241 shares of Intra-Cellular Therapies stock. The stock was sold at an average price of $50.01, for a total value of $362,122.41.
• On Friday, February 24th, Mark Neumann sold 4,046 shares of Intra-Cellular Therapies stock. The stock was sold at an average price of $47.12, for a total value of $190,647.52.
• On Tuesday, February 21st, Mark Neumann sold 3,898 shares of Intra-Cellular Therapies stock. The stock was sold at an average price of $47.01, for a total value of $183,244.98.

Intra-Cellular Therapies Stock Performance

Shares of Intra-Cellular Therapies stock opened at $45.31 on Wednesday. The company has a market capitalization of $4.32 billion, a PE ratio of -16.66 and a beta of 1.13. The company has a 50-day simple moving average of $48.16 and a two-hundred day simple moving average of $49.20. Intra-Cellular Therapies, Inc. has a one year low of $42.01 and a one year high of $66.00.

Intra-Cellular Therapies (NASDAQ:ITCI – Get Rating) last announced its earnings results on Wednesday, March 1st. The biopharmaceutical company reported ($0.45) EPS for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.17. The business had revenue of $87.87 million during the quarter, compared to the consensus estimate of $86.97 million. Intra-Cellular Therapies had a negative net margin of 102.37% and a negative return on equity of 35.88%. The firm’s revenue was up 242.3% on a year-over-year basis. During the same period in the previous year, the company posted ($1.05) earnings per share. On average, equities analysts predict that Intra-Cellular Therapies, Inc. will post -2.42 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Intra-Cellular Therapies

Large investors have recently modified their holdings of the business. Harvest Fund Management Co. Ltd purchased a new stake in shares of Intra-Cellular Therapies during the fourth quarter worth about $31,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Intra-Cellular Therapies during the third quarter worth about $41,000. Coppell Advisory Solutions Corp. purchased a new stake in shares of Intra-Cellular Therapies during the fourth quarter worth about $47,000. Northern Oak Wealth Management Inc. purchased a new stake in shares of Intra-Cellular Therapies during the second quarter worth about $51,000. Finally, Quantbot Technologies LP purchased a new stake in shares of Intra-Cellular Therapies during the third quarter worth about $55,000. Hedge funds and other institutional investors own 86.95% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. Royal Bank of Canada decreased their price objective on Intra-Cellular Therapies from $75.00 to $71.00 and set an “outperform” rating for the company in a report on Thursday, March 2nd. Needham & Company LLC restated a “buy” rating and issued a $70.00 price objective on shares of Intra-Cellular Therapies in a report on Wednesday, March 1st. Cantor Fitzgerald restated an “overweight” rating and issued a $83.00 price objective on shares of Intra-Cellular Therapies in a report on Wednesday, February 1st. Mizuho decreased their price objective on Intra-Cellular Therapies from $72.00 to $66.00 in a report on Friday, March 3rd. Finally, JPMorgan Chase & Co. decreased their price objective on Intra-Cellular Therapies from $59.00 to $58.00 and set an “overweight” rating for the company in a report on Thursday, March 9th. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, Intra-Cellular Therapies presently has a consensus rating of “Moderate Buy” and a consensus target price of $69.40.

Intra-Cellular Therapies Company Profile

(Get Rating)

Intra-Cellular Therapies, Inc operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS.